Annovis Bio shares jump 20.61% intraday as director Hoffman buys $1.5M in stock and company secures U.S. patent for buntanetap.

Annovis Bio surged 20.61% intraday as Director Hoffman increased his stake by buying 713,800 shares at $2.10 each on April 2, investing around $1.5 million, raising his ownership to approximately 27.7%. Additionally, the company announced it received U.S. Patent No. 12,582,632 B2 covering the use of its oral candidate buntanetap for the prevention and treatment of neurological damage caused by brain infections.